126 related articles for article (PubMed ID: 34649959)
1. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
2. Ranitidine Use and Risk of Upper Gastrointestinal Cancers.
Adami HO; Trolle Andersen I; Heide-Jørgensen U; Chang ET; Nørgaard M; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2302-2308. PubMed ID: 34620629
[TBL] [Abstract][Full Text] [Related]
3. Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study.
Cardwell CR; McDowell RD; Hughes CM; Hicks B; Murchie P
Am J Gastroenterol; 2021 Aug; 116(8):1612-1619. PubMed ID: 34028367
[TBL] [Abstract][Full Text] [Related]
4. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
5. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018.
Iwagami M; Kumazawa R; Miyamoto Y; Ito Y; Ishimaru M; Morita K; Hamada S; Tamiya N; Yasunaga H
Drug Saf; 2021 Mar; 44(3):361-371. PubMed ID: 33247391
[TBL] [Abstract][Full Text] [Related]
6. Prescription changes in patients with gastrointestinal disorders after withdrawal of ranitidine: a nationwide population-based cohort study.
Ku M; Je NK
Curr Med Res Opin; 2023 Feb; 39(2):197-203. PubMed ID: 36519289
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
8. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
9. Acid suppressants use and the risk of dementia: A population-based propensity score-matched cohort study.
Wu CL; Lei WY; Wang JS; Lin CE; Chen CL; Wen SH
PLoS One; 2020; 15(11):e0242975. PubMed ID: 33253311
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors and the risk of acute kidney injury in cancer patients receiving immune checkpoint inhibitors: A Danish population-based cohort study.
Munch PV; Nørgaard M; Heide-Jørgensen U; Jensen SK; Birn H; Christiansen CF
Int J Cancer; 2024 Apr; 154(7):1164-1173. PubMed ID: 37983738
[TBL] [Abstract][Full Text] [Related]
13. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
Liew JW; Peloquin C; Tedeschi SK; Felson DT; Zhang Y; Choi HK; Terkeltaub R; Neogi T
Arthritis Care Res (Hoboken); 2022 Dec; 74(12):2059-2065. PubMed ID: 35245410
[TBL] [Abstract][Full Text] [Related]
14. Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori.
Kumar S; Goldberg DS; Kaplan DE
Dig Dis Sci; 2022 May; 67(5):1822-1830. PubMed ID: 33856609
[TBL] [Abstract][Full Text] [Related]
15. Ranitidine Use and Incident Cancer in a Multinational Cohort.
You SC; Seo SI; Falconer T; Yanover C; Duarte-Salles T; Seager S; Posada JD; Shah NH; Nguyen PA; Kim Y; Hsu JC; Van Zandt M; Hsu MH; Lee HL; Ko H; Shin WG; Pratt N; Park RW; Reich CG; Suchard MA; Hripcsak G; Park CH; Prieto-Alhambra D
JAMA Netw Open; 2023 Sep; 6(9):e2333495. PubMed ID: 37725377
[TBL] [Abstract][Full Text] [Related]
16. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
17. Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National Databases.
Arinze JT; de Ridder MAJ; Vojinovic D; van Ballegooijen H; Markov E; Duarte-Salles T; Rijnbeek P; Verhamme KMC
Drug Saf; 2023 Dec; 46(12):1353-1362. PubMed ID: 37907775
[TBL] [Abstract][Full Text] [Related]
18. Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing.
Park KH; Pai J; Song DG; Sim DW; Park HJ; Lee JH; Jeong KY; Pan CH; Shin I; Park JW
Clin Exp Allergy; 2016 Apr; 46(4):631-9. PubMed ID: 26764898
[TBL] [Abstract][Full Text] [Related]
19. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction.
Sehested TSG; Gerds TA; Fosbøl EL; Hansen PW; Charlot MG; Carlson N; Hlatky MA; Torp-Pedersen C; Gislason GH
J Intern Med; 2018 Mar; 283(3):268-281. PubMed ID: 29024109
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
